Company Profile For BTG Plc

BTG plc is engaged in development and commercialization of life science technologies. The Company in-licenses, develops and commercializes pharmaceuticals and has a pipeline of development programmes targeting neurological and other disorders, including varicose veins. The Company also has a revenue stream of payments and royalties from out-licensed products. The Company operates in two segments: life sciences, which is engaged in the acquisition, development and commercialization of pharmaceutical and other medical technologies, and technology commercialization, which is engaged in the commercialization of technology outside the life sciences area. On December 4, 2008, it acquired Protherics PLC, which is principally involved in the research, development, manufacture and sale of pharmaceutical products and drugs for use in the treatment of human diseases.

BRIEF: For the fiscal year ended 31 March 2009, BTG plc's revenues increased 13% to £84.8M. Net loss totaled £13.1M vs. an income of £8.8M. Revenues reflect increase in income from the Technology commercialisation segments & increase sales from United Kingdom. Net loss reflects decrease in gross profit, increase in research & development expenses, loss on amount written off on investments and the presence of impairment & other costs.